Who is sponsoring NCT02877901?

NCT02877901 is sponsored by Mansoura University.

What condition does NCT02877901 study?

NCT02877901 studies Nocturnal Incontinence.

What drugs are being tested in NCT02877901?

Interventions: long acting tolterodine 4 mg, placebo.

What is the status of NCT02877901?

NCT02877901 is currently COMPLETED.

Last reviewed 2017-12-25 · How we verify

Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder. A Randomized Placebo-controlled Crossover Study

NCT02877901 Phase 2/Phase 3 COMPLETED

It is a prospective randomized- placebo control crossover study to evaluate the effect of long acting tolterodine (anticholinergic) in improving and treating nocturnal incontinence in patient after radical cystectomy and orthotopic urinary diversion. patients will be randomly allocated into two groups. one will receive the drug and the other will receive placebo. continence status will be evaluated before and 4 weeks after treatment by the number of pads used and the ICIQ-UI short form questionnaire. This is followed by two weeks of drug washout then reevaluation of the continence status and each group will be crossed over and lastly will be evaluated again.

Details

Lead sponsor	Mansoura University
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	120
Start date	2016-05
Completion	2017-12

Conditions

Nocturnal Incontinence

Interventions

long acting tolterodine 4 mg
placebo

Primary outcomes

improvement of nocturnal incontinence — 10 weeks
the score of ICIQ- UI short form questionnaire